WNTinib
WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC) . WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation[1].
Product Specifications
CAS Number
2770091-44-4
Product Name Alternative
APS-8-100-2
UNSPSC
12352005
Target
Apoptosis; Wnt
Type
Reference compound
Related Pathways
Apoptosis; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wntinib.html
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C=C1F)OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(C(F)(C(F)(F)F)F)C=C3
Molecular Formula
C22H16F6N4O3
Molecular Weight
498.38
References & Citations
[1]Rialdi A, et al. WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nat Cancer. 2023 Aug;4 (8) :1157-1175.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
